Vaccine News and Research

Latest Vaccine News and Research

IDRI receives $1 million RHSC grant to eliminate leprosy

Leprosy, otherwise referred to as Hansen's Disease, is one of the most ancient diseases known to humans. Although the World Health Organization declared leprosy to be under control in many previously endemic countries, most experts agree that current approaches to treating the disease are not sufficient to eliminate the disease as a public health problem. Currently, 1.6 billion people are considered at risk of exposure to leprosy, while over 800 new cases occur every day.

9 Mar 2012

Maxygen reports net loss of $2.2 million for fourth quarter 2011

Maxygen, Inc., a biopharmaceutical company, today announced financial and business results for the quarter and year ended December 31, 2011.

9 Mar 2012

PharmAthene revenue increases to $24.3M for year ended December 31, 2011

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, today reported its financial and operational results for the year ended December 31, 2011.

9 Mar 2012

Viewpoints: Wilensky on bipartisan Medicare reform; Mass. 2006 health law and 2012 GOP politics; Reinstating advanced care planning

The Super Tuesday exit polls yielded a mountain of data in 10 states, but the most telling single statistic may have been in Massachusetts, which Mitt Romney won in a largely uncontested rout. Yet believe it or not, he still lost on health care. The exit poll asked voters their opinion of the "Massachusetts Health Care Law," with the options of Did Not Go Far Enough, About Right and Went Too Far. Remarkably, 51% said the bill went too far, while only 37% said it was about right, and 6% said not far enough.

9 Mar 2012

Doctor associated with MMR vaccine and autism link wins High Court appeal

Professor John Walker-Smith had been found guilty of professional misconduct following claims he took part in unapproved research that suggested links between the vaccine, bowel disease and autism. Professor Walker-Smith lost his license to practice in May 2010 along with Dr Andrew Wakefield, who led the research. A General Medical Council’s ‘fitness to practice’ panel found both men guilty of misconduct over the way the work was conducted after 217 days of deliberation – the longest disciplinary case in the body’s 150- year history.

8 Mar 2012

Bellicum raises $20M in Series B financing

Bellicum Pharmaceuticals, Inc. today announced that it has raised $20 million in a Series B financing. The funding will be used to advance its lead CaspaCIDe and DeCIDe programs through Phase 2 clinical development.

8 Mar 2012

Positive phase II trial results from Circassia's ragweed allergy therapy

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that its ragweed allergy therapy has achieved positive results in a key phase II clinical trial.

8 Mar 2012

Queen's receives NICH&S grant to create vaccine against Pseudomonas

Queen's University Belfast scientists working on a vaccine to combat Pseudomonas have received a financial boost from Northern Ireland Chest Heart and Stroke.

8 Mar 2012

Combining radiation therapy with ipilimumab shows promise against melanoma

Research published today in the New England Journal of Medicine by scientists at the Ludwig Institute for Cancer Research (LICR) and Memorial Sloan-Kettering Cancer Center (MSKCC) showed that combining targeted radiation therapy with immunotherapy (ipilimumab), fostered a strong immune response and a favorable clinical outcome in a patient with melanoma, the most dangerous form of skin cancer.

8 Mar 2012

Intellect Neurosciences receives U.S. patent allowance for ANTISENILIN to treat AD

Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases announced today that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent claims covering the company's ANTISENILIN monoclonal antibody platform technology for the treatment and prevention of Alzheimer's disease.

7 Mar 2012

MTPC, Medicago partner to develop and commercialize three new vaccines

Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced the establishment of a strategic alliance with Mitsubishi Tanabe Pharma Corporation (MTPC) through the execution of a Master Research Collaboration Agreement.

6 Mar 2012

Microneedle vaccine patches may effectively protect against flu

Recent research found that microneedle vaccine patches are more effective at delivering protection against influenza virus in mice than subcutaneous or intramuscular inoculation. A new, detailed analysis of the early immune responses by the Emory and Georgia Tech research team helps explain why the skin is such fertile ground for vaccination with these tiny, virtually painless microneedles.

6 Mar 2012

Mount Sinai researchers argue different views of how to safely handle H5N1 flu viruses

In the controversy surrounding the newly developed strains of avian H5N1 flu viruses, scientists and policy makers are struggling with one question in particular: what level of biosafety is best for studying these potentially lethal strains of influenza? In a pair of commentaries, researchers from the Mount Sinai School of Medicine in New York and the University of Michigan argue their different views of how to safely handle H5N1 flu viruses.

6 Mar 2012

Scientists identify novel protein expressed by breast cancer cells

A team of scientists at the University of California, San Diego Moores Cancer Center has identified a novel protein expressed by breast cancer cells - but not normal adult tissues - that could provide a new target for future anti-cancer drugs and treatments.

6 Mar 2012

Sun-dried tomatoes may be contaminated with hepatitis A virus: Officials warn

The Health Protection Agency (HPA) said two confirmed cases of the infection had been found to have an identical strain to three cases reported in England and confirmed at HPA Colindale in 2010. Both people had recently eaten sun-dried tomatoes.

5 Mar 2012

Interaction sends letter to CIA head protesting use of vaccination plot to find Bin Laden in Pakistan

"An alliance of 200 U.S. aid groups has written to the head of the CIA to protest against its use of a doctor to help track Osama bin Laden, linking the agency's ploy to the polio crisis in Pakistan," the Guardian reports, noting Pakistan recorded the highest number of polio cases in the world last year.

5 Mar 2012

Bill Gates meets MTBVAC TB vaccine researchers in Spain

On 21 February Bill Gates met with Dr. Carlos Martin of the University of Zaragoza and members of his team in Madrid, Spain. The scientists are working on the development of MTBVAC, a new vaccine against tuberculosis (TB). Gates showed great interest in the scientific background of MTBVAC, the most advanced vaccine based on attenuation of Mycobacterium tuberculosis.

5 Mar 2012

Inovio's SynCon vaccine for HPV types 6 and 11 induces CD8+ T cells in mice

Inovio Pharmaceuticals, Inc. announced today that its SynCon therapeutic vaccine for human papillomavirus (HPV) types 6 and 11, which are associated with head & neck cancers and genital warts, among other conditions, induced strong antigen-specific CD8+ T cells in mice.

5 Mar 2012

VOA examines constitutional debate in Nigeria over government's right to require polio vaccination

"A constitutional debate is under way in Nigeria over whether the government can prosecute parents who refuse to have their children vaccinated against polio, or if it has the power to force parents to have their children vaccinated against any communicable disease," VOA News reports.

3 Mar 2012

EC grants marketing authorization for Baxter's VEPACEL to treat influenza A

Baxter International Inc. announced today that the European Commission (EC) has granted marketing authorization for VEPACEL in all European Union (EU) Member States, as well as Iceland, Liechtenstein and Norway.

From Baxter International Inc. 2 Mar 2012